OrganTech Grants Domestic Manufacturing License for Cell-Derived Components, Including the 'Third Cell'
Key facts
- OrganTech Grants Domestic Manufacturing License for Cell-Derived Components, Including the 'Third Cell'
- OrganTech has granted a manufacturing license for its proprietary 'third cell' (hair follicle regeneration-supporting cell) and related cell-derived components to Kojin Bio. The partnership aims to accelerate hair regenerative medicine and related product development.
- Source: PR Times
- Date: May 20, 2026
Direct answer
OrganTech has granted a manufacturing license for its proprietary 'third cell' (hair follicle regeneration-supporting cell) and related cell-derived components to Kojin Bio. The partnership aims to accelerate hair regenerative medicine and related product development.
- Citation
- OrganTech Grants Domestic Manufacturing License for Cell-Derived Components, Including the 'Third Cell' (May 20, 2026), PR Times
- Source
- PR Times
- Date
- May 20, 2026
OrganTech has granted a manufacturing license for its proprietary 'third cell' (hair follicle regeneration-supporting cell) and related cell-derived components to Kojin Bio. The partnership aims to accelerate hair regenerative medicine and related product development.
📋 Article Processing Timeline
- 📰 Published: May 20, 2026 at 19:00
- 🔍 Collected: May 20, 2026 at 10:31
- 🤖 AI Analyzed: May 21, 2026 at 13:32 (27h 0m after Collected)
OrganTech, a biotech company committed to creating innovative medical technologies to improve health and quality of life (QOL), announces that it has granted a domestic manufacturing license for cell-derived components of hair follicle-derived cells—specifically the 'third cell' (hair follicle regeneration-supporting cell) and dermal papilla cells—to Kojin Bio.
This marks the second business collaboration between OrganTech and Kojin Bio, following their joint project on three-dimensional artificial skin. Hair follicle epithelial stem cells and dermal papilla cells play crucial roles in the regeneration of hair follicle organs. In February 2026, OrganTech became the first in the world to discover the 'third cell,' known as the 'hair follicle regeneration-supporting cell,' which induces hair follicle organ regeneration. Meanwhile, Kojin Bio has been selling high-performance culture media that enables the cultivation of dermal papilla cells and hair follicle regeneration-supporting cells derived from hair follicles.
OrganTech is licensing the manufacturing rights for these cell-derived components within Japan to Kojin Bio. By utilizing Kojin Bio's proprietary cell culture media and processing technologies, OrganTech aims to expand its hair and skin-related businesses.
OrganTech positions this manufacturing license grant to Kojin Bio as a key initiative in its hair-related cell business. Moving forward, the company intends to accelerate the research and development of hair regenerative medicine (including cell transfer therapy, hair follicle primordial transplantation, and regenerated hair follicle transplantation) and diverse products utilizing cell-derived components, in collaboration with medical institutions and various partners.
In the fields of hair and skin, OrganTech aims to contribute to a society that ensures safety, security, and high QOL by addressing various healthcare challenges such as alopecia, skin diseases, and aging through the accumulation of scientific evidence and technological development.
This marks the second business collaboration between OrganTech and Kojin Bio, following their joint project on three-dimensional artificial skin. Hair follicle epithelial stem cells and dermal papilla cells play crucial roles in the regeneration of hair follicle organs. In February 2026, OrganTech became the first in the world to discover the 'third cell,' known as the 'hair follicle regeneration-supporting cell,' which induces hair follicle organ regeneration. Meanwhile, Kojin Bio has been selling high-performance culture media that enables the cultivation of dermal papilla cells and hair follicle regeneration-supporting cells derived from hair follicles.
OrganTech is licensing the manufacturing rights for these cell-derived components within Japan to Kojin Bio. By utilizing Kojin Bio's proprietary cell culture media and processing technologies, OrganTech aims to expand its hair and skin-related businesses.
OrganTech positions this manufacturing license grant to Kojin Bio as a key initiative in its hair-related cell business. Moving forward, the company intends to accelerate the research and development of hair regenerative medicine (including cell transfer therapy, hair follicle primordial transplantation, and regenerated hair follicle transplantation) and diverse products utilizing cell-derived components, in collaboration with medical institutions and various partners.
In the fields of hair and skin, OrganTech aims to contribute to a society that ensures safety, security, and high QOL by addressing various healthcare challenges such as alopecia, skin diseases, and aging through the accumulation of scientific evidence and technological development.
FAQ
What is the name of the cell type that OrganTech licensed to Kojin Bio in 2023?
The cell type licensed is called the 'third cell,' which supports hair follicle regeneration.
Which company received a manufacturing license from OrganTech for cell-derived components in 2023?
Kojin Bio received the manufacturing license for OrganTech's proprietary cell-derived components.
What specific product component did OrganTech license to Kojin Bio in 2023?
OrganTech licensed the 'third cell,' a hair follicle regeneration-supporting cell, to Kojin Bio.
In what year did OrganTech grant Kojin Bio rights to manufacture its third cell technology?
OrganTech granted Kojin Bio manufacturing rights for the third cell technology in 2023.
What is the primary purpose of the third cell developed by OrganTech and licensed to Kojin Bio?
The third cell supports hair follicle regeneration and is used in regenerative medicine development.